Form 8.5 (EPT/RI) - Ophir Energy Plc   FORM 8.5 (EPT/RI)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
9
Form 8.5 (EPT/RI) - Ophir Energy Plc

  FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

1.         KEY INFORMATION

(a) Name of exempt principal trader: 

Investec Bank plc

 
(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
  Use a separate form for each offeror/offeree
 

Ophir Energy plc
(c) Name of the party to the offer with which exempt principal trader is connected:

 
 

Investec are Joint Broker to Ophir Energy plc

 
 d) Date dealing undertaken: 

7th February 2019

 
(e) Has the EPT previously disclosed, or is it today disclosing, in respect of any other party to this offer?No

2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a)        Purchases and sales

Class of relevant securityPurchases/ sales

 
Total number of securitiesHighest price per unit paid/received
(pence)

 
Lowest price per unit paid/received
(pence)
 

Ordinary
Shares

 
 

Purchases
 

1,000,000
 

54.7
 

  54.6
 

Ordinary
Shares
 

 

Sales
 

1,000,000
 

54.73829
 

54.63822

(b)        Derivatives transactions (other than options)

Class of relevant securityProduct description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securitiesPrice per unit
  

 
   

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType
e.g. American, European etc.
Expiry dateOption money paid/ received per unit
        

(ii)        Exercising

Class of relevant securityProduct description
e.g. call option
Number of securitiesExercise price per unit
    

 

(d)        Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing
e.g. subscription, conversion
DetailsPrice per unit (if applicable)
  

 
  

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

3.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
If there are no such agreements, arrangements or understandings, state “none”
 

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
 

None


 

8th February 2019
  

Rich White
  

0207 597 5462

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading